Objective: Clinical research on psychosocial and behavioral medicine interventions has burgeoned in the past two decades, so much so that sole reliance on standard no-treatment control conditions may no longer be appropriate or feasible. We discuss the ethical, theoretical, scientific, and statistical considerations that shape current clinical outcomes research for psychosocial and behavioral medicine interventions. Method and Results: Secondary analysis of a psychosocial randomized trial {N = 127) illustrates some of these points. Conclusions: A new design for randomized clinical trials is described that does not require a no-treatment control group, and that reveals dose-response relationships between interventions and treatment outcomes.
INTRODUCTION
With the increased public awareness and use of self-help approaches (1) , formal evaluations of psychological and alternative therapy interventions have become both increasingly necessary and challenging. Zeal for scientific rigor has led behavioral researchers to emulate pharmaceutical placebo-controlled trials for testing interventions. This design may, however, compromise the ethicality, validity, generalizability, and utility of our studies. Patients are consistently faced with multiple intervention options, with little evidence to help them decide which intervention would best fit their needs. In addition, the wide availability of such interventions makes it difficult for current and future trials to compare an active intervention to a placebo control group. This is an important problem for current and future outcomes research in either psychosomatic or behavioral medicine. The purpose of this study is to discuss the: a) ethical; b) theoretical; c) scientific; and d) statistical issues relevant to the control group dilemma for psychosocial and behavioral medicine interventions. We will illustrate these points using data from a 2-year psychosocial randomized trial of 127 multiple sclerosis patients. This trial compared two active interventions, a coping skills group and peer telephone support. Treatment outcomes included clinical health, role performance, adaptability, and well-being (see Schwartz (2) for primary analyses; see Schwartz and Rogers (3) for description of coping skills group intervention). Finally, an alternative design will be proposed for future intervention research.
Ethical considerations concerning control conditions in intervention research are determined by the state of knowledge at the time a study is initiated. The ethical principle of equipoise, which is central to the protection of human research subjects, states that patients should be assured of receiving the best available standard therapy in any therapeutic study (4) . Clinical research over the past several decades has documented reduced psychological morbidity and, in some cases, prolonged survival among medically ill populations who received a psychosocial intervention (5) (6) (7) (8) . Given these documented effects, it may no longer be appropriate or feasible to rely solely on the standard no-treatment control condition.
Placebo controls are a usual design alternative to no-treatment controls. However, placebo-controlled clinical trials may be problematic due to the "resentful demoralization" of control group participants (9) . This demoralization may lead people assigned to control groups to seek out treatment similar to the active intervention. It may not only be difficult to get study participants to agree not to seek similar types of social support via friends or informal lay groups from other sources. It may also be inappropriate or unethical to ask them to avoid using a resource that has been well-documented to be health-enhancing (10) .
This ethical issue exists even when the evidence is debated regarding the efficacy of psychosocial interventions and the medical community remains neutral. Any evidence of the positive effects of psychosocial interventions can result in a perception of benefit on the part of many patients and providers, and can lead to the problem of resentful demoralization among control group participants.
Identifying an effective placebo for an intervention may be further complicated by the concern for integrity on the part of the provider. For example, a clinician may be unwilling to participate in a clinical trial because the control condition is either not comparable (eg, no treatment) or misrepresents the treatment (eg, nondirective group educational meetings instead of cognitive-behavioral group therapy).
A fraudulent control condition thus poses ethical problems both for the patient and for the provider, and may consequently influence the credibility of the intervention (11). The above-noted issues are primarily relevant to placebo controls, and are not as problematic when one uses active comparison conditions, rather than attention-placebo control conditions without formal therapy. The present work examines other types of control procedures that may be appropriate for current research on psychosocial and behavioral medicine interventions.
Another concern involves the concept of informed consent. All research studies on human subjects must obtain informed consent from study participants at study entry. This consent form must accurately reflect the concept of randomization and must clearly describe the treatment(s) being investigated. Such a requirement is based on the assumption that informed patients will make cogent decisions. However, research on informed consent suggests that the frame of reference may bias patients' willingness to participate (12) . For example, patients are more likely to participate in an experimental drug therapy if the consent form expresses the outcomes in terms of probability of living, rather than probability of dying (13) . Thus, clearly explaining the concept of randomization (ie, an equal chance of being assigned to either treatment condition) and the likelihood of being assigned to a "control" condition may hinder study accrual. Nonetheless, the language of the consent form must be sensitive to the misunderstandings and biases of patients while accurately reflecting the risks and benefits associated with the interventions being evaluated.
The Ethics of Economic Considerations Related to the above ethical considerations are the economic factors that can influence trial design. For example, if resources are scarce then trials should be designed according to clinically significant and economically feasible outcomes, rather than focusing solely on statistical significance (14) . Thus, the control condition might use a less expensive, albeit less effective, commonly used treatment for a given condition rather than a no-treatment control. Although a no-treatment control would reduce the cost of the study due to lower sample size requirements (see Statistical Considerations below), the comparison conditions should be designed according to the treatments and effect sizes that are economically feasible in the real-world setting. Consequently, the outcomes tools used should be reliable, valid, sensitive, and specific to maximize the revealed effect difference between interventions.
THEORETICAL CONSIDERATIONS
It is often difficult to define an adequate placebo control in psychosocial or behavioral medicine research. The rationale for placebo control conditions is to protect against the perpetuation of spurious or superstitious therapy procedures (15) . Designing a placebo for a pharmaceutical trial is often straightforward (eg, sugar pill, saline injection, etc.). In contrast, achieving a successful placebo-control design in behavioral medicine research involves distinguishing between nonspecific factors and unspecified active therapeutic ingredients (16) . Nonspecific factors are common to different psychosocial or behavioral medicine interventions. They can include social support, a therapeutic alliance, a plausible explanation for the client's problem, and a credible treatment rationale. These factors, however, are typically not inactive therapeutic ingredients, but rather unspecified active ingredients common to almost all psychological interventions. Accordingly, it is difficult, if not impossible, to construct a nonspecific treatment condition that does not have active therapeutic ingredients. For example, a credible treatment rationale generates positive expectations for improvement within the client. An optimistic outcome expectancy has been associated with greater use of active coping strategies in recovering from illness (17) (18) , greater adherence to health care recommendations, and better health outcomes (17) . The optimal placebo control should encompass none of the active ingredients of the therapy under evaluation. This distinction assumes that the investigators know what aspects of the intervention are the "active ingredients," whether they be specified or unspecified. Such an assumption may prove problematic, particularly in the case of multi-component treatment packages and especially in light of the hidden benefits of control conditions that become apparent only in subsequent analyses.
People who volunteer to participate in randomized trials may be different than nonvolunteers. They may have a stronger sense of self-efficacy (19) , may be more focused on finding an effective treatment (20) , and thus may already be ready to take action to modify problematic behaviors (21) . Although this problem can influence the external validity of all research studies, it is of particular relevance for intervention studies. Their internal validity can be moderated by patient selection factors. For example, patient preferences can have a differential impact on treatment outcomes. This concept is illustrated by a secondary analysis of data from Schwartz' (2) randomized trial comparing two psychosocial interventions. Before randomization, study participants were asked to indicate which treatment they would prefer to receive. Both interventions, a coping skills group and peer telephone support, were perceived to be beneficial. The former was perceived to be slightly more attractive. Fortunately, the randomization process resulted in balanced preferences across study arms. Of interest, secondary analysis of this trial data revealed that patients who were randomized to the treatment they preferred tended to report improvement on psychosocial role limitations after 2 months as measured by the Sickness Impact Profile (23) (p<.10). In contrast, those who were not randomized to their preferred intervention reported no change ( Figure 1 ). This finding may suggest that patients respond better when they are matched with their preferred treatment, and that choice enhances outcome. Taking into consideration the patient's preference and other sociodemographic characteristics may be an expedient way to maximize treatment effectiveness.
Psychosocial Role Limitations Score Fig. 1 . Impact of prerandomization preference on psychosocial role limitations. Patients who were randomized to the treatment they preferred tended to report improvement on psychosocial role limitations after 2 months, whereas those who were not randomized to their preferred intervention reported no change.
For example, Gale et al. (23) found that matching an intervention to the patient's level of education and disability yielded a more effective treatment than an omnibus, global intervention. Tailoring a treatment to the individual's specific situation and preferences may also be more consistent with the theoretical basis of interventions, resulting in more effective targeting of clinical interventions in everyday practice. This matching may also be appropriate in cases of limited resources (ie, small studies) or larger "real-world" effectiveness studies (ie, Phase IV trials). The implications of such tailoring on statistical power will be discussed below. The use of comparison conditions brings into focus a concern that may not seem relevant when placebo controls are used: the patient's interpretation of the mechanisms of change. The assumptions inherent in the clinical trial method and its concept of therapeutic benefit may be profoundly at variance with the participant's own assumptions and concept of benefit (24) . For example, Lorig et al. (25) reported that patients with osteoarthritis who reported decreased pain also reported increased self-efficacy, but not changes in pain-reducing behaviors. Changes in the outcome were not associated with behavior change, but rather with an increase in self-efficacy. Patient beliefs may also have a clear relationship to the ability or willingness of patients to become involved in treatments. For example, Williams and Thorn (26) found that patients' beliefs that their pain had no explanation were consistently associated with poor compliance. Future studies might address the mechanisms of change by using daily study methods (eg, diaries, random beeper-driven data collection), such as those developed by Stone and Shiftman (27) and Affleck et al. (28) .
A final theoretical consideration is related to regression to the mean. For example, a control condition can show changes that suggest improvement among patients who are below the mean on a health status measure at baseline or entry into a study, or that suggest a worsening condition among patients who have increased health status scores at baseline. Thus, if eligibility criteria focus on patients who are below the mean on a given outcome, then placebos may result in high rates of good outcomes regardless of the intervention (29) .
An alternative explanation is that changes in outcomes may result from response shift phenomenon. This refers to the idea that individuals facing a significant health challenge may experience a change in internal standards of expectations for optimal functioning (30) (31) (32) . Acute health-state changes may have an impact on psychological morbidity, followed by accommodation and adaptation to the functional limitations imposed by the illness. This shift explains how an individual's life satisfaction may not be directly related to their functional status. Bach and Tilton (33) found, for example, that individuals with tetraplegia who were dependent on a ventilator reported higher life satisfaction than tetraplegics who were able to breathe independently. Individuals facing a significant health challenge may scale down their expectations of health, may be more appreciative of the social resources that support their daily living activities, and may be making significant adjustments in the importance of life domains (33) . These individual values may also play an important role in determining the complex interrelationships underlying quality of life. For example, satisfaction with one's functional status has been found to be related to psychological well-being only among individuals who viewed the abilities being evaluated as very important (34) . Interventions that improve social support may affect patient values, priorities, and appreciation of the resources they have. These social support interventions may allow them to maximize their quality of life despite important physical set-backs. Thus, it may be hard to differentiate change due to active interventions and truly improved functional status from change due to patient accommodation to level of function.
This concept is illustrated with data from the above-mentioned randomized trial (2) . In this example, level of neurologic disability is measured by the Expanded Disability Status Scale (EDSS) score (35) , a categorical measure where a score of zero refers to normal function, 6 refers to relying on a cane to ambulate, and 10 refers to death due to multiple sclerosis. The Ferrans and Powers' Quality of Life Index (36) was used to measure overall life satisfaction. Figure 2 shows that the association between level of neurologic disability and overall life satisfaction is discontinuous, with a dramatic drop at a disability level which just precedes reliance on a cane to ambulate (ie, an EDSS score of 6). Once people begin to rely on this ambulation device, their overall satisfaction increases considerably, despite the general downward slope over level of disability. This illustration suggests that adaptation to functional decline is discontinuous, particularly during times of great change or disease activity. This phenomenon may introduce variability in the outcomes of a clinical trial, and suggests that the randomization should be stratified according to the patient's disease stability or activity. Subsequent comparisons could examine the impact of disease stability or activity on the clinical and psychosocial outcomes of interest. An alternative design for clinical research that adjusts for intraindividual variability by having patients serve as their own control will be proposed below.
THE SCIENTIFIC ISSUES
We conclude that successful randomization of patients to a no-treatment control condition is not always appropriate and may not represent the best control procedure. Consequently, an appropriate al- Fig. 2 . Overall satisfaction by neurological disability. The association between level of neurologic disability and overall life satisfaction is discontinuous, with a dramatic drop at a disability level which just proceeds reliance on a cane to ambulate (ie, an EDSS score of 6). Once people begin to rely on this ambulation device, their overall satisfaction increases considerably, despite the general downward slope over level of disability. This illustration suggests that adaptation to functional decline is discontinuous, particularly during times of great change or disease activity.
Psychosomatic Medicine 59:362-371 (1997) ternative is a trial that compares two interventions that have similar perceived value, yet involve different assumptions about mechanisms of action and likely outcomes (37) . There are several distinctions that may assist investigators in defining optimal comparison conditions: a) the phase of the study; b) the comparable credibility of the interventions; c) the comparable accessibility of the interventions; and d) the treatment trade-offs.
The Phase of the Study As in pharmaceutical research, psychosocial and behavioral medicine research should be implemented in phases ( Table 1 ). The initial phase would focus on developing and pretesting the interventions (Phase I). The next phase would determine the appropriate frequency, duration, and intensity of a specific treatment intervention, and define the relevant outcomes (Phase II). The third phase would evaluate the efficacy of the intervention as compared with the current standard treatment(s). A fourth phase would confirm the effectiveness of the interventions in a "real world" setting. Identifying the phase of the research can help the investigator to design appropriate control conditions. For example, Phase I would not require a control condition, and Phase II might benefit from comparing various "doses" of the intervention (eg, frequency of contact with the provider). Phase III would compare the new treatment to the current standard (eg, primary medical care alone vs primary care supplemented by behavioral intervention). An appropriate Phase III trial might also compare two common psychosocial interventions that involve different assumptions about mechanisms of action and likely outcomes (37) . A Phase IV trial might use a quasi-experimental (eg, case-control) design to evaluate the effect of the intervention in a clinical setting where patients self-select to receive a particular intervention. In such a study, case-mix adjustment (38) (ie, statistically adjusting for relevant medical and sociodemographic characteristics) may be necessary to control for pretreatment differences between cases and controls.
These Phase IV trials could build on past research by using the psychosocial factors that predicted change in the Phase III trial as: a) eligibility criteria for participation or; b) stratification variables. For example, Irvine and Logan (39) found that the most anxious participants were the least likely to demonstrate a decrease in diastolic blood pressure in response to stress management therapy. A Phase IV trial on behavior change interventions might consequently use baseline anxiety as a stratification variable, and supplement the intervention with an antianxiety intervention before teaching behavior change. This approach thus takes into account what may be considered barriers to changes that must be addressed in the design of the intervention.
Such Phase IV trials might also be ideal for evaluating the long-term effects of treatment. Such trials could similarly evaluate the long-term effects of control conditions to ascertain that they do not make people worse. It is also possible that control conditions may actually make people better over the long term. Future research could address different maintenance strategies, such as booster individual, group, or telephone sessions, or relapse prevention training during the initial intervention phase. Future research could also test different theory-based approaches to maintaining behavior change. The Credibility of the Interventions The comparability of interventions from the patient's perspective can be formally evaluated by measuring the patients' perceptions of the interventions' credibility both initially and after completing the prescribed treatment. This assessment can be done using the Credibility of Treatment Rating Scale developed by Borkovec and Nau (40) . This scale has items to measure patients' perceptions of how logical the treatment is, its likelihood of helping the patient's ailments, their confidence in recommending it to a friend, and its overall credibility. This scale has been suggested for use in trials to validate the placebo control condition (41) .
Another approach to evaluating the equal valence CONTROL GROUP DILEMMA of the two conditions is to evaluate prerandomization preference. By asking study participants what intervention they would prefer, the investigator has a straightforward way to identify the intervention with the more salient therapeutic appeal.
The Accessibility of the Interventions Interventions must be equally accessible to be comparable. If one treatment requires more effort from the patient or the support network, the trial may suffer from differential dropout and prerandomization selection bias. For example, in the Schwartz trial, 36% of the patients who refused to participate cited as the primary reason problems getting to the hospital if they were to be randomized to the coping skills group (2) . Those who were randomized were also more likely to have a higher income and to be disabled from work (42) .
If the comparison conditions are designed to involve different assumptions about mechanisms of action, then differential dropout may be expected. For example, in the Schwartz trial, the coping skills group was expected to influence quality-of-life outcomes via changes in coping flexibility and directive social support. In contrast, the peer telephone support intervention was expected to influence wellbeing via nondirective social support. The study implementation should correct for this bias. This correction can be accomplished by encouraging study participants at study entry to continue to provide data even if they drop out of their randomized intervention. This allows analysis by intentionto-treat, in which all eligible patients are included in the analysis of results, regardless of compliance with protocol (43) . This approach provides a more accurate assessment of treatment efficacy as it relates to actual clinical practice. This analytic approach also counteracts the tendency documented by Shaw et al. (44) for patient attrition to result in more homogenous patient groups. This attrition minimizes the external validity of the study results.
Another aspect of the comparable accessibility of the interventions refers to the frequency of contact with the provider. Weinberger et al. (45) found that gathering health status information once a month from patients resulted in improvements in health status. These changes may reflect the Hawthorne effect (46) , which originally referred to enhanced work productivity due to attention from others and currently often refers to the increased well-being simply due to attention from others. They may also reflect the above-mentioned response shift phenomenon, in which patients' adaptation and shifting internal referents result in improved reported health-related quality of life despite an absence of actual health state changes (30) (31) (32) . The cognizant investigator might consequently track the comparability of treatments by documenting and comparing attendance, and by strictly adhering to parallel data collection time lines for the two treatment arms.
Treatment Trade-Offs A final consideration that arises in comparing two active treatments is the risk of negative effects in one or both conditions. As in pharmaceutical studies, treatment-related "toxicities" should be carefully monitored. One psychosocial study done by Parker et al. (47) compared inpatient medical care alone to care supplemented with a thorough arthritis educational intervention. They reported that the provision of information alone seemed to have negative effects, such as reported increased pain and impairment. Parker speculated that giving patients information about their disease but providing them with no guidance on how to cope or control the disease may be detrimental. Consequently patients in the educational intervention may become more anxious, and increasingly concerned about their present symptoms and the future course of their disease. The educational intervention may have made them seem worse on self-report measures due to their increased awareness of their condition.
Appropriate analytic techniques can evaluate the treatment trade-offs by explicitly comparing the treatment benefits and costs. For example, the Extended Quality-adjusted Time Without Symptoms and Toxicity (Q-TWiST) Method (48, 49) evaluates treatment trade-offs and comprehensive treatment outcomes by using patient-derived preference values to weight quality-of-life outcomes. This method facilitates the use of profile measures of quality of life, objective functional outcomes, and social cost. The resulting score summarizes the perspectives of the patient, the provider, and social cost, and is expressed in Quality-adjusted Life Years (QALYs), which can be used in cost-effectiveness and costutility analyses.
STATISTICAL CONSIDERATIONS
A critical issue in the design of a randomized trial concerns statistical power. Simply stated, an investigator's power to detect meaningful differences de-pends on three parameters: the sample size, the magnitude of the effect that is deemed clinically significant, and the inherent variability of the outcome measure. The power curve is exponential, requiring few subjects per group for large effects, and large numbers of subjects per group for moderate and small effects (Figure 3) . Study designs that maximize statistical power are placebo-controlled randomized trials with longitudinal follow-up (50) . Given the noted problems with placebo-controlled studies, the modern investigator must consider statistical power issues in the context of intervention studies of two active treatments. The more one controls for nonspecific effects, however, the smaller the anticipated effect size and hence the larger the sample size requirements (51) . Similarly, the more one tailors the intervention to the individual patient, the more heterogeneous the resulting comparison groups. This heterogeneity also reduces the statistical power due to the increased variability in the outcomes. The increased cost and challenge of implementing such a large study might lead one to seek an alternative design that integrates the ethical, theoretical, scientific, and statistical concerns while maintaining parsimony.
AN ALTERNATIVE DESIGN
We propose an alternative study design for clinical research to illustrate strategies that respond to many of the above issues. This design is a randomized three-arm variation of a standard crossover trial. In trial. An investigator's power to detect meaningful differences depends on three parameters: the sample size, the magnitude of the effect which is deemed clinically significant, and the inherent variability of the outcome measure. Crossover designs are statistically efficient, requiring approximately one-quarter the number of subjects as a parallel-arm study for the same power. the first two arms, patients would receive active treatment followed by a control condition (arm a in Figure 4 ), or vice versa (arm b in Figure 4 ). The patients randomized to the third arm (arm c in Figure 4 ) would receive the active treatment for the entire duration of the other treatment arms (ie, treatment and control). This arm would allow the investigator to address the longer-term effect of the intervention, without dramatically increasing the sample size.
The control condition in the first two arms (ie, arms a and b in Figure 4 ) would be a wait-list that could involve standard care or no treatment. The decision about whether to use a standard care or no-treatment wait-list control would depend on the usual treatment approach for the study population and symptom complex. If there were a standard treatment for the symptom complex (eg, pharmaceuticals, support groups, antidepressants), then the wait-list patients would have normal access to them. If the syndrome is one that does not interfere significantly with daily life and is not threatening to health then a no-treatment control would be appropriate. If the trial population is in crisis, then the control group would get standard care.
This design has the advantage of avoiding the need to create a placebo-control, minimizing the ethical dilemma by providing treatment to all patients. The enhanced statistical efficiency of the crossover de- would receive the active treatment for entire duration of the treatment. This design allows one to examine the longer-term effect of the intervention, dose-response, and order effects, and facilitates an in-depth study of the process of change. Further, it avoids the need for a no-treatment or placebo control condition, as all patients receive some treatment protocol over the course of the trial.
CONTROL CROUP DILEMMA
sign would allow the use of individually tailored interventions, and thus increase the clinical validity of the trial results. Such treatment protocol heterogeneity would normally reduce the statistical power of the trial and lead to an expensive increase in the number of patients required to detect a difference between treatments. However, crossover designs use patients as their own controls and are thereby statistically efficient: they require approximately onequarter the number of patients per study arm as those required for a standard parallel design ( Figure  4 ) (52) . This estimation assumes that the withinsubject is equal to the between-subject variability (52). This increased power would offset the reduced statistical power of the protocol heterogeneity. The proposed three-arm crossover design allows for an examination of dose-response relationships, whereas the standard crossover trial limits the investigator's ability to learn about the effects of longerterm intervention. The three arms provide information about the effects of shorter-term interventions (ie, arm a or b) and about longer-term interventions (ie, arm c). The investigator might seek to evaluate the maintenance of effects over time (ie, carry-over effects) by shorter-term interventions using data from arm a or design the study to include a washout period between treatment and follow-up so that the follow-up could be a clear no-treatment comparison condition. Consequently, treatment outcomes should be measured pre-and postintervention as well as before and after the washout and no-treatment periods (labeled D on Figure 4) . Thus, the proposed design responds to the standard problem of crossover designs, that of not allowing the investigator to examine whether continued adherence to an intervention produces benefits over a long period of time or follow-up.
This use of the three-arm crossover trial data is similar to an approach used by Thoresen (53) to evaluate the long-term impact of a behavioral intervention for postinfarction patients who had participated in a crossover trial. They were able to show that the larger the "dose" received of the behavioral intervention, the more behavior change and health benefit (53) . This third arm also facilitates an in-depth study of the process of change. The response shift phenomenon could be explicitly addressed if data collection included a retrospective pretest (54) , in which patients are asked to rate their quality of life both currently and thinking back on how they were doing at the last data collection time point. This "then-test" (54) captures response shift, and subsequent statistical modeling can be used to tease apart adaptation and shifting internal referents.
Finally, the three-arm crossover design can allow the investigator to evaluate order effects, which may prove illuminating for hypothesis generation. For example, assume that Condition A is nonspecific support (eg, social support), Condition B is coping effectiveness training (ie, the experimental intervention), and Condition C is two cycles of the coping effectiveness training. The design is: AB, BA, and BB. Suppose that analysis of the results revealed that AB was better than BA and BB. The interpretation, framed as hypothesis generation, might be that social support prepared patients for the coping skills training, whereas coping skills training given first inadvertently increased resistance in some patients. Therefore, this three-arm crossover design could identify possible timing or staging effects of the different therapies.
The appropriateness of the three-arm crossover trial will depend on the objectives of the research. If the intervention is not expected to have extended carry-over effects (eg, acupuncture, massage), then no washout period will be required. If the intervention is expected to have brief carry-over effects (eg, pharmacotherapy), then a brief washout period may be necessary. If the intervention is a cognitive-behavioral treatment for stress management, then a washout period may not be feasible because it may not be possible to remove the effects of the exposure. If the objective is to study carry-over effects, then a standard parallel-arm design would be appropriate (ie, treatment vs control with no crossover). For example, one could compare the experimental treatment, best standard care, and a wait-list control or usual care (if the latter is not the same as the comparison condition). The latter design will be expensive to implement due to the sample size requirements in parallel-arm trials comparing active treatments (ie, small effects sizes, see Figure 3 ). Further, it may not be feasible among proactive patients who refuse to participate if randomized to a wait-list control. The three-arm crossover design is a feasible and appropriate design if carry-over effects are not the primary end points. It represents one of several possible approaches to design.
The phase of the study is an important consideration for the design. If the goal of the study is to learn how long the treatment effects last, then a Phase II study may be appropriate. This Phase II study could be used to determine the duration of the washout period by evaluating outcomes for a period of weeks or months after treatment termination until the effect size is significantly diminished. After the washout C. E. SCHWARTZ et al.
period is known, a Phase III study could be implemented using the above three-arm crossover trial design to address efficacy and dose-response relationships in comparison with other active treatments or attention-placebo conditions. Data collection time-points should be implemented at equal intervals throughout the study, to facilitate outcomes comparisons during the washout and wait-list periods.
SUMMARY
We have described the ethical, theoretical, scientific, and statistical considerations that currently shape clinical research in psychosocial and behavioral medicine outcomes research. We propose an alternative design for randomized trials that mitigates some of these concerns, and that is economical and statistically efficient.
